Prosecution Insights
Prosecution Insights
6 pending office actions • 2 art units • 4 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 4 (67%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIWARI, VYOMA SHUBHAM | 3 | 30.2% | +46.7% |
| DUFFY, BRADLEY | 1 | 54.6% | +45.4% |
| WU, JULIE ZHEN QIN | 1 | 61.5% | +52.1% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253721 | ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY | WU, JULIE ZHEN QIN | 22d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18165623 | COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS | CANELLA, KAREN A | 46d overdue |
| 18253721 | ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY | WU, JULIE ZHEN QIN | 22d |
| 17480501 | CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS | TIWARI, VYOMA SHUBHAM | 22d |
| 18553326 | POLYPEPTIDES TARGETING HLA-A*11 AND METHODS OF USE THEREOF | DUFFY, BRADLEY | — |
| 17480476 | ENGINEERED IMMUNE CELLS WITH MULTIPLEX AND LOCALIZED ACTIVITY | TIWARI, VYOMA SHUBHAM | — |
| 17480462 | ENGINEERING IMMUNE CELLS BASED ON ANTIGEN LEVELS | TIWARI, VYOMA SHUBHAM | — |
| Art Unit | Apps |
|---|---|
| 1643 | 3 |
| 1634 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18553326 | POLYPEPTIDES TARGETING HLA-A*11 AND METHODS OF USE THEREOF | DUFFY, BRADLEY | 1643 | §112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18253721 | ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY | WU, JULIE ZHEN QIN | 1643 | §102§103§112Other | Non-Final OA | 22d | Pending | May 19, 2023 |
| 18165623 | COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS | CANELLA, KAREN A | 1643 | §102§103§112DP | Final Rejection | 46d overdue | Pending | Feb 07, 2023 |
| 17480476 | ENGINEERED IMMUNE CELLS WITH MULTIPLEX AND LOCALIZED ACTIVITY | TIWARI, VYOMA SHUBHAM | 1634 | §112 | Non-Final OA | — | Pending | Sep 21, 2021 |
| 17480501 | CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS | TIWARI, VYOMA SHUBHAM | 1634 | §112 | Non-Final OA | 22d | Pending | Sep 21, 2021 |
| 17480462 | ENGINEERING IMMUNE CELLS BASED ON ANTIGEN LEVELS | TIWARI, VYOMA SHUBHAM | 1634 | §112 | Non-Final OA | — | Pending | Sep 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial